Synapse - Works

Results (13087)

A phase 1b trial of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia

Meeting Abstract

Gangat, N.; Foran, J. M.; Halpern, A. B.; Rampal, R. K.; Novikov, N.; Buch, A.; Pelletier, O.; Savage, W.; Tefferi, A.
Blood (2023)

Fulltext@MSK | Save

Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis

Meeting Abstract

Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
Blood (2023)

Fulltext@MSK | Save

Preliminary safety results of the open-label phase of a 2-part phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic cell transplantation

Meeting Abstract

Ponce, D. M.; Kosuri, S.; Khera, N.; Defilipp, Z.; Lichter, D. I.; Peled, J. U.; van den Brink, M. R. M.; Brady, K.; Puhl, M. D.; Glick, G.; more...
Blood (2023)

Fulltext@MSK | Save

PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7

Meeting Abstract

Kunimoto, H.; Miura, A.; Sagisaka, M.; Ito, M.; Honma, D.; Tsutsumi, S.; Sakuma, T.; Ohashi, T.; Teranaka, H.; Ikeda, J.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes for patients with classical Hodgkin lymphoma who relapse after autologous stem cell transplant in the era of novel therapies

Meeting Abstract

Stuver, R.; Drill, E.; Ganesan, N.; Baron, K.; Casper, E.; Chang, T.; Desai, S. H.; Falade, A. S.; Galasso, N.; Herrera, A. F.; more...
Blood (2023)

Fulltext@MSK | Save

A pro-inflammatory gene signature characterizes a better risk aged AML patient group in ECOG-ACRIN Cancer Research Group's clinical trial E3999

Meeting Abstract

Neelamraju, Y.; Rapaport, F.; Gandara, J. A.; Dunham, N.; Fan, H.; Lee, T.; Prajapati, S.; Sheridan, C.; Wang, L.; Cripe, L. D.; more...
Blood (2023)

Fulltext@MSK | Save

AFM13 in combination with allogeneic natural killer cells (AB-101) in relapsed or refractory Hodgkin lymphoma and CD30+ peripheral T-cell lymphoma: A phase 2 study (LuminICE)

Meeting Abstract

Moskowitz, A.; Harstrick, A.; Emig, M.; Overesch, A.; Pinto, S.; Ravenstijn, P.; Schlüter, T.; Rubel, J.; Rebscher, H.; Graefe, T.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes of patients with primary mediastinal B-cell lymphoma refractory or relapsed after frontline R-EPOCH chemotherapy

Meeting Abstract

Bakos, J.; Escribano Serrat, S.; Sawalha, Y.; Moskowitz, A.; Crawford, A.; Brooks, T. R.; Hill, B. T.; Falade, A. S.; Merryman, R. W.; Kamdar, M.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of peri-transplant radiation on outcomes in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplant

Meeting Abstract

Baron, K.; Drill, E.; Ganesan, N.; Merryman, R. W.; Mei, M. G.; Stuver, R.; Desai, S. H.; Falade, A. S.; Iyengar, S.; Micallef, I.; more...
Blood (2023)

Fulltext@MSK | Save

Comparison of bendamustine versus fludarabine/cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy

Meeting Abstract

Landego, I.; Nemirovsky, D.; Devlin, S. M.; Wills, B.; Parascondola, A.; Saldia, A.; Dahi, P. B.; Tomas, A. A.; Ip, A.; Suh, H. C.; more...
Blood (2023)

Fulltext@MSK | Save